

March 16, 2022



LIXTE Biotechnology Holdings, Inc. to Present at MedInvest Pharmaceutical and Biotechnology Investor Conference

PASADENA, CA, March 16, 2022 (GLOBE NEWSWIRE) -- [LIXTE Biotechnology Holdings, Inc. \(Nasdaq: LIXT\)](#), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will present at the MedInvest Pharmaceutical and Biotechnology Investor Conference to be held March 28 - April 1, 2022. Lixte's presentation will take place on Thursday, March 31 at 12:00 - 12:20pm EDT.

Event and Registration: www.medinvestconferences.com

Date: Thursday, March 31 at 12:00 - 12:20pm EDT

Location: Virtual

Presentation: Available livestream and on-demand

LIXTE Founder and CEO John S. Kovach, M.D. will deliver a company overview as well as an update on LIXTE's novel, first-in-class lead clinical compound, LB-100, a PP2A inhibitor.

About Lixte Biotechnology Holdings, Inc.

[LIXTE Biotechnology Holdings, Inc. \(Nasdaq: LIXT\)](#), is a clinical-stage pharmaceutical company founded to identify new targets for cancer drug development. Major drivers of cancer are defects in the switches that turn the biochemical pathways in cells on or off. Most cancer research over the past 30 years has focused on the "on" switches because the "off" switches, especially the master "off" switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. LIXTE has achieved a breakthrough with its novel, first-in-class lead clinical compound and PP2A inhibitor, LB-100, by demonstrating that LB-100 is readily tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly improve outcomes for patients undergoing various chemotherapies or immunotherapies. LIXTE's new approach has no known competitors and is covered by a comprehensive patent portfolio. Initial proof-of-concept clinical trials are in progress.

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," "anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or

the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at www.sec.gov/edgar.shtml

Lixte Contact:

info@lixte.com

General Phone: (631) 830-7092

Investor Phone: (888) 289-5533



Source: Lixte Biotechnology Holdings, Inc.